Identification of immune cell infiltration pattern and related critical genes in metastatic castration-resistant prostate cancer by bioinformatics analysis

被引:7
|
作者
Fan, Caibin [1 ]
Lu, Wei [2 ]
Li, Kai [1 ]
Zhao, Chunchun [1 ]
Wang, Fei [1 ]
Ding, Guanxiong [3 ]
Wang, Jianqing [1 ]
机构
[1] Nanjing Med Univ, Affiliated Suzhou Hosp, Suzhou Municipal Hosp, Gusu Sch,Dept Urol, 26 Daoqian Rd, Suzhou 215000, Jiangsu, Peoples R China
[2] Suzhou Vocat Hlth Coll, Sch Nursing, Suzhou, Jiangsu, Peoples R China
[3] Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Immune infiltration; metastatic castration resistant prostate cancer (mCRPC); RNA sequencing; bioinformatics analysis; immunotherapy; DIFFERENTIAL EXPRESSION ANALYSIS; BREAST-CANCER; IMMUNOTHERAPY; SURVIVAL; INTERLEUKIN-2; PROLIFERATION; ENZALUTAMIDE; ANTAGONISTS; INHIBITION; DIAGNOSIS;
D O I
10.3233/CBM-203222
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) is the lethal stage of prostate cancer and the main cause of morbidity and mortality, which is also a potential target for immunotherapy. METHOD: In this study, using the Approximate Relative Subset of RNA Transcripts (CIBERSORT) online method, we analysed the immune cell abundance ratio of each sample in the mCRPC dataset. The EdgeR (an R package) was used to classify differentially expressed genes (DEGs). Using the Database for annotation, visualisation and interactive exploration (DAVID) online method, we performed functional enrichment analyses. STRING online database and Cytoscape tools have been used to analyse protein-protein interaction (PPI) and classify hub genes. RESULTS: The profiles of immune infiltration in mCRPC showed that Macrophages M2, Macrophages M0, T cells CD4 memory resting, T cells CD8 and Plasma cells were the main infiltration cell types in mCRPC samples. Macrophage M0 and T cell CD4 memory resting abundance ratios were correlated with clinical outcomes. We identified 1102 differentially expressed genes (DEGs) associated with the above two immune cells to further explore the underlying mechanisms. Enrichment analysis found that DEGs were substantially enriched in immune response, cell metastasis, and metabolism related categories. We identified 20 hub genes by the protein-protein interaction network analysis. Further analysis showed that three critical hub genes, CCR5, COL1A1 and CXCR3, were significantly associated with prostate cancer prognosis. CONCLUSION: Our findings revealed the pattern of immune cell infiltration in mCRPC, and identified the types and genes of immune cells correlated with clinical outcomes. A new theoretical basis for immunotherapy may be given by our results.
引用
收藏
页码:363 / 377
页数:15
相关论文
共 50 条
  • [31] Contemporary management of metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Sternberg, Cora N.
    CURRENT OPINION IN UROLOGY, 2011, 21 (03) : 241 - 247
  • [32] Re: Olaparib for Metastatic Castration-resistant Prostate Cancer
    Di Lorenzo, Giuseppe
    Autorino, Riccardo
    EUROPEAN UROLOGY, 2020, 78 (05) : 767 - 768
  • [33] Drug therapies for metastatic castration-resistant prostate cancer
    El-Bahesh, Ehab
    Finianos, Antoine
    Alfaraj, Abeer
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2015, 11 (17) : 2395 - 2403
  • [34] Histologic Spetrum of Metastatic Castration-Resistant Prostate Cancer
    Huang, Jiaoti
    Yin, Yu
    Thomas, George
    True, Lawrence
    Beer, Tomasz M.
    Gleeve, Martin
    Witte, Owen
    Stuart, Josh
    Evans, Chris
    Foye, Adam
    Youngren, Jack
    Small, Eric
    LABORATORY INVESTIGATION, 2017, 97 : 231A - 231A
  • [35] Re: Olaparib for Metastatic Castration-resistant Prostate Cancer
    Cumberbatch, Marcus
    Condon, Benjamin
    Lawrentschuk, Nathan
    Murphy, Declan G.
    EUROPEAN UROLOGY, 2021, 79 (02) : 319 - 320
  • [36] The obesity paradox in metastatic castration-resistant prostate cancer
    Martini, Alberto
    Shah, Qainat N.
    Waingankar, Nikhil
    Sfakianos, John P.
    Tsao, Che-Kai
    Necchi, Andrea
    Montorsi, Francesco
    Gallagher, Emily J.
    Galsky, Matthew D.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2022, 25 (03) : 472 - 478
  • [37] Drug resistance in metastatic castration-resistant prostate cancer
    Bostjan Seruga
    Alberto Ocana
    Ian F. Tannock
    Nature Reviews Clinical Oncology, 2011, 8 : 12 - 23
  • [38] Monitoring of treatment for metastatic castration-resistant prostate cancer
    Hinz, Stefan
    AKTUELLE UROLOGIE, 2017, 48 (03) : 225 - 229
  • [39] Drug resistance in metastatic castration-resistant prostate cancer
    Seruga, Bostjan
    Ocana, Alberto
    Tannock, Ian F.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (01) : 12 - 23
  • [40] Comment on: Rucaparib in castration-resistant, metastatic prostate cancer
    Brandt, Maximilian
    AKTUELLE UROLOGIE, 2024, 55 (02) : 98 - 98